NCT07174063View on ClinicalTrials.gov

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 26, 2025

Primary Completion Date

June 18, 2027

Study Completion Date

June 18, 2027

Conditions
Metastatic Prostate Cancer (mCRPC)
Interventions
DRUG

JSB462

300 mg or 100 mg once a day (QD) with food

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY